Guggenheim Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Guggenheim Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,488	Closed	-$28K	–	2665
2018 Q1	$28K	Buy	13,488 +82	+0.6%	+$176	﹤0.01%	2730
2017 Q4	$27K	Sell	13,406 -1,674	-11%	-$3.47K	﹤0.01%	2661
2017 Q3	$20K	Buy	15,080 +2	+0%	+$2	﹤0.01%	2749
2017 Q2	$24K	Sell	15,078 -1,636	-10%	-$3.15K	﹤0.01%	2773
2017 Q1	$53K	Buy	16,714 +12	+0.1%	+$30	﹤0.01%	2730
2016 Q4	$22K	Buy	16,702 +47	+0.3%	+$61	﹤0.01%	2844
2016 Q3	$26K	Buy	+16,655	New	+$25.6K	﹤0.01%	2803
2015 Q1	–	Sell	-183,942	Closed	-$3.11M	–	3092
2014 Q4	$3.11M	Buy	+183,942	New	+$2.68M	0.01%	1408
2014 Q1	–	Sell	-184,336	Closed	-$2.55M	–	3377
2013 Q4	$2.55M	Buy	184,336 +24,520	+15%	+$346K	0.01%	1562
2013 Q3	$2.79M	Buy	159,816 +40,007	+33%	+$766K	0.01%	1401
2013 Q2	$1.95M	Buy	+119,809	New	+$3.71M	0.01%	1555

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Guggenheim Capital's INFI Position: Q2 2018 in Review

Guggenheim Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2018, closing a stake of 13,488 shares — an estimated $28K sold.

Guggenheim Capital first reported a position in INFI in Q2 2013 and held it in 11 quarters. The position peaked at $3.11M in Q4 2014. 64 funds tracked by Wall St. Rank hold INFI as of Q2 2018.

Guggenheim Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 13,488 Infinity Pharmaceuticals, Inc. shares in Q2 2018, an estimated $28K.
Guggenheim Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 11 quarters.
Guggenheim Capital's Infinity Pharmaceuticals, Inc. position peaked at $3.11M in Q4 2014.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.